MBX Biosciences (MBX) Assets Average (2024 - 2026)

MBX Biosciences has reported Assets Average for 3 years, with the latest figure at $418.9 million in Q1 2026.

• Quarterly Assets Average rose 62.86% year-over-year to $418.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $418.9 million (up 62.86% YoY) and the FY2025 annual result came in at $326.8 million, up 85.33% from the prior year.
• Assets Average advanced to $418.9 million in Q1 2026 per MBX's latest filing, from $392.6 million in the prior quarter.
• Over five years, Assets Average peaked at $418.9 million in Q1 2026 and troughed at $238.7 million in Q2 2025.
• A 3-year average of $316.5 million and a median of $295.6 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2025 and 2026: Assets Average surged 42.52% in 2025, then jumped 62.86% in 2026.
• Over 3 years, Assets Average stood at $275.5 million in 2024, then soared by 42.52% to $392.6 million in 2025, then climbed by 6.7% to $418.9 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $418.9 million, $392.6 million, and $315.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.